Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified β-cyclodextrin

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 67, Issue 2, 2007, Pages 531-539

  Figueiras, Ana ^a,b   Carvalho, Rui A ^a   Ribeiro, Laura ^b   Torres Labandeira, Juan J ^c   Veiga, Francisco J B ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Cyclodextrin; Dissolution profile; Inclusion complex; Methyl cyclodextrin; Omeprazole; Physicochemical characterization

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; BETA CYCLODEXTRIN; KLEPTOSE; METHYL BETA CYCLODEXTRIN; OMEPRAZOLE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL MODIFICATION; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE FORM; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; FREEZE DRYING; INCLUSION COMPLEX; INFRARED SPECTROSCOPY; KNEADING; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; SCANNING ELECTRON MICROSCOPY; SOLID STATE; SPRAY DRYING; STOICHIOMETRY; ULTRAVIOLET SPECTROSCOPY; X RAY DIFFRACTION;

BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CIRCULAR DICHROISM; ENZYME INHIBITORS; HEAT; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, SCANNING; MODELS, CHEMICAL; OMEPRAZOLE; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; X-RAY DIFFRACTION;

EID: 34547692974     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2007.03.005     Document Type: Article

References (36)

1. Howden C.W. Clinical pharmacology of omeprazole. Clin. Pharmacokinet. 20 (1990) 39-49
2. Sarisuta N., Tourtip T., and Chuarcharoern S. Chemical stability and mechanism of degradation of omeprazole in solution. Thai. J. Pharm. Sci. 22 (1998) 81-88
3. Marzocchi L., Moyano J.R., Rossi A., Muñoz P., Arias M.J., and Giordano F. Current status of ATPase proton pump inhibitor complexation with cyclodextrins. Biolog. J. Armenia 53 (2001) 176-193
4. Lee D.Y., Shin H.S., Bae S.K., and Lee M.G. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous omeprazole in rats. Biopharm. Drug Dispos. 27 (2006) 209-218
5. Riedel A., and Leopold C.S. Degradation of omeprazole induced by enteric polymer solutions and aqueous dispersions: HPLC investigations. Drug Dev. Ind. Pharm. 31 (2005) 151-160
6. Castronuovo G., and Niccoli M. Thermodynamics of inclusion complexes of natural and modified cyclodextrins with propranolol in aqueous solution at 298 K. Bioorg. Med. Chem. 14 (2006) 3883-3887
7. Loftsson T., and Brewester M. Pharmaceutical applications of cyclodextrins. Drug solubilization and stabilization. J. Pharm. Sci. 85 (1996) 1017-1025
8. Szejtli J. Cylodextrin in drug formulations: Part I. Pharm. Technol. Int. 3 (1991) 15-23
9. Challa R., Ahuja A., Ali J., and Kharl R.K. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 6 (2005) E 329-E 357
10. Szejtli J. Medicinal application of cyclodextrins. Med. Res. Rev. 14 (1994) 353-386
11. Grosse P.Y., Pinguet F., Joulia J.M., Astre C., and Bressolle F. High-performance liquid chromatography assay for methyl-β-cyclodextrin in plasma and cell lysate. J. Chromatogr. B 694 (1997) 219-226
12. Higuchi T., and Connors A.K. Phase-solubility techniques. In: Reill C.N. (Ed). Advances in Analytical Chemistry and Instrumentation (1965), Wiley-Intersciences, New York 117-212
13. Tapia M.J., Burrows H.D., and García J.M. A.A.C.C. Pais, Lanthanide ion interaction with a crown ether methacrylic polymer, poly (1,4,7,10-tetraoxacyclododecan-2-ymethyl methacrylate), as seen by spectroscopic, calorimetric, and theoretical studies. Macromolecules 37 (2004) 856-862
14. Arias M.J., Moyano J.R., Muñoz P., Ginés J.M., Justo A., and Giordano F. Study of omeprazole-γ-cyclodextrin complexation in the solid state. Drug Dev. Ind. Pharm. 26 (2000) 253-259
15. Ribeiro L., Loftsson T., Ferreira D., and Veiga F. Investigation and Physicochemical characterization of vinpocetine-sulfobutyl ether β-cyclodextrin binary and ternary complexes. Chem. Pharm. Bull. 51 (2003) 914-922
16. Veiga M.D., Díaz P.J., and Ahsan F. Interactions of griseofulvin with cyclodextrins in solid binary systems. J. Pharm. Sci. 87 (1998) 891-900
17. Richardson J.C., Dettmar P.W., Hampson F.C., and Melia C.D. Oseophageal bioadhesion of sodium alginate suspensions: particle swelling and mucosal retention. Eur. J. Pharm. Sci. 23 (2004) 49-56
18. U.S.P. XXVIII The United States Pharmacopoeia. 25th ed., United States Pharmacopeial Convention Inc., Rockville, 2005.
19. Khan K.A. The concept of dissolution efficiency. J. Pharm. Pharmacol. 27 (1975) 48-49
20. Wimmer R., Aachmann F.L., Larsen K.L., and Petersen S.B. NMR diffusion as a novel tool for measuring the association constant between cyclodextrin and guest molecule. Carbohydr. Res. 337 (2002) 841-849
21. Echezarreta-López M.M., Perddomo-López I., Estrada E., Vila-Jato J.L., and Torres-Labandeira J.J. Utility of nuclear magnetic resonance spectroscopy to characterize the structure of dexamethasone sodium phosphate inclusion complexes with cyclodextrins in solution and to analyze potential competitive effects. J. Pharma. Sci. 91 (2002) 1536-1547
22. Figueiras A., Sarraguça J.M.G., Carvalho R.A., Pais A.A.C.C., and Veiga F.J.B. Interaction of omeprazole with a methylated derivative of β-cyclodextrin: phase solubility. NMR spectroscopy and molecular simulation. Pharm. Res. (2006)
23. Clas S., Dalton C.R., and Hancock B.C. Differential scanning calorimetry: applications in drug development. Res. Focus 2 (1999) 311-320
24. Ruiz M.A., Reyes I., Parera A., and Gallardo V. Determination of the stability of omeprazole by means of differential scanning calorimetry. J. Therm. Anal. Cal. 51 (1998) 29-35
25. Pinto L.M.A., Fraceto L.F., Santana M.H.A., Pertinhez T.A., Junior S.O., and de Paula E. Physico-chemical characterization of benzocaine-β-cyclodextrin inclusion complexes. J. Pharm. Biom. Anal. 39 (2005) 956-963
26. Ning L., Zhang Y.-H., Wu Y.-N., Xiong X.-L., and Zhang Y.-H. Inclusion complex of trimethoprim with β-cyclodextrin (short communication). J. Pharm. Biom. Anal. 39 (2005) 824-829
27. G. Zingone, F. Rubessa, Preformulation study of the inclusion complex warfarin-[beta]-cyclodextrin, Int. J. Pharm. Proceedings of the 5th Central European Symposium on Pharmaceutical Technology and Biotechnology, 291 (2005) 3-10.
28. Yap K.L., Liu X., Thenmozhiyal J.C., and Ho P.C. Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis. Eur. J. Pharm. Sci. 25 (2005) 49-56
29. Rajendrakumar K., Madhusudan S., and Pralhad T. Cyclodextrin complexes of valdecoxib: properties and anti-inflammatory activity in rat. Eur. J. Pharm. Biopharm. 60 (2005) 39-46
30. Pralhad T., and Rajendrakumar K. Study of freeze-dried quercetin-cyclodextrin binary systems by DSC, FT-IR, X-ray diffraction and SEM analysis. J. Pharm. Biom. Anal. 34 (2004) 333-339
31. Lee P.S., Y Han J., Song T.W., Sung J.H., Kwon O.S., Song S., and Chung Y.B. Physicochemical characteristics and bioavailability of a novel intestinal metabolite of ginseng saponin (IH901) complexed with [beta]-cyclodextrin. Int. J. Pharm. 316 (2006) 29-36
32. Ruan L.P., Yu B.Y., Fu G.M., and Zhu D. Improving the solubility of ampelopsin by solid dispersions and inclusion complexes. J. Pharm. Biomed. Anal. 38 (2005) 457-464
33. Sinha V.R., Anitha R., Ghosh S., Nanda A., and Kumria R. Complexation of celecoxib with -cyclodextrin: characterization of the interaction in solution and in solid state. J. Pharm. Sci. 94 (2005) 676-687
34. Fernandes C.M., Vieira M.T., and Veiga F.J.B. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur. J. Pharm. Sci. 15 (2002) 79-88
35. Naidu N.B., Chowdary K.P.R., Murthy K.V.R., Satyanarayana V., Hayman A.R., and Becket G. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J. Pharm. Biomed. Anal. 35 (2004) 75-86
36. Ribeiro L., Ferreira D.C., and Veiga F.J.B. In vitro controlled release of vinpocetine-cyclodextrin-tartaric acid multicomponent complexes from HPMC swellable tablets. J. Control Release 103 (2005) 325-339